排名前五的靶点	数量

DNase I(脱氧核糖核酸酶1)	1
PDL1(程序性死亡配体1)	1
RARs(维甲酸受体家族)	1
SARS-CoV-2 S protein(新冠病毒刺突蛋白)	1
SMN2(运动神经元存活蛋白)	1

关联

项与 Roche Products Pty Ltd. 相关的药物

Glofitamab

格菲妥单抗

靶点

CD20 x CD3

作用机制

CD20抑制剂 [+2]

在研机构

Roche Holding AG [+9]

原研机构

F. Hoffmann-La Roche Ltd.

在研适应症

复发性弥漫性大B细胞淋巴瘤 [+22]

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

加拿大

首次获批日期2023-03-24

Faricimab

法瑞西单抗

靶点

Ang2 x VEGF-A

作用机制

Ang2抑制剂 [+1]

在研机构

F. Hoffmann-La Roche Ltd. [+11]

原研机构

F. Hoffmann-La Roche Ltd.

在研适应症

视网膜静脉阻塞 [+12]

非在研适应症

湿性黄斑变性

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2022-01-28

Casirivimab/Imdevimab

卡西瑞单抗/伊德单抗

靶点

SARS-CoV-2 S protein

作用机制

SARS-CoV-2 S protein抑制剂

在研机构

Roche Registration GmbH [+4]

原研机构

Roche Registration GmbH [+1]

在研适应症

新型冠状病毒感染

非在研适应症

慢性病 [+1]

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2020-11-21

项与 Roche Products Pty Ltd. 相关的临床试验

NCT04962126 / Active, not recruiting临床2期IIT

Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapy

This single-arm phase II interventional study aims to assess disease response to, and toxicity of, a combination of obinutuzumab and atezolizumab, with or without radiotherapy, in treatment naive Follicular Lymphoma.
The study will involve an induction phase and a maintenance phase for responding participants, for up to 24 months. Response to treatment will be monitored using medical imaging and clinical assessment.

开始日期2021-08-17

申办/合作机构

Olivia Newton-John Cancer Research Institute

[+3]

NCT02564770 / CompletedN/A

A Retrospective Chart Review of the Use of MabThera (Rituximab) for the Treatment of Rheumatoid Arthritis (RA) in Australian Rheumatology Practice

This is a cross-sectional, observational study examining the factors leading to the therapeutic decision to use MabThera (rituximab) in participants with RA. Routine rheumatology clinical practice data of participants who are being or have been treated with rituximab for RA will be collected and analysed in this chart review.

开始日期2012-01-01

申办/合作机构

Hoffmann-La Roche, Inc.

[+1]

ACTRN12610000694011 / Not yet recruiting临床1期

A Multi-center, Randomized, Observer-blinded, Multiple–Ascending-Dose, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5310074 FollowingMultiple Intravenous Administrations in Subjects with Psoriatic Arthritis

开始日期2010-10-15

申办/合作机构

Roche Products Pty Ltd.

100 项与 Roche Products Pty Ltd. 相关的临床结果

登录后查看更多信息

0 项与 Roche Products Pty Ltd. 相关的专利（医药）

登录后查看更多信息

项与 Roche Products Pty Ltd. 相关的文献（医药）

2023-06-15·The AAPS journal

Streamlining Food Effect Assessment - Are Repeated Food Effect Studies Needed? An IQ Analysis.

Article

作者: Bransford, Philip ; Chung, John ; Dolton, Michael ; Parrott, Neil ; Heimbach, Tycho ; Stamatopoulos, Konstantinos ; Moir, Andrea ; Belubbi, Tejashree ; Kesisoglou, Filippos ; Pepin, Xavier ; Tistaert, Christophe ; Wagner, Christian ; Kulkarni, Priyanka ; Dodd, Stephanie ; Sharma, Pradeep ; Basu, Sumit ; Vaidhyanathan, Shruthi ; Lin, Wen ; Ren, Xiaojun ; Riedmaier, Arian Emami

Current regulatory guidelines on drug-food interactions recommend an early assessment of food effect to inform clinical dosing instructions, as well as a pivotal food effect study on the to-be-marketed formulation if different from that used in earlier trials. Study waivers are currently only granted for BCS class 1 drugs. Thus, repeated food effect studies are prevalent in clinical development, with the initial evaluation conducted as early as the first-in-human studies. Information on repeated food effect studies is not common in the public domain. The goal of the work presented in this manuscript from the Food Effect PBPK IQ Working Group was to compile a dataset on these studies across pharmaceutical companies and provide recommendations on their conduct. Based on 54 studies collected, we report that most of the repeat food effect studies do not result in meaningful differences in the assessment of the food effect. Seldom changes observed were more than twofold. There was no clear relationship between the change in food effect and the formulation change, indicating that in most cases, once a compound is formulated appropriately within a specific formulation technology, the food effect is primarily driven by inherent compound properties. Representative examples of PBPK models demonstrate that following appropriate validation of the model with the initial food effect study, the models can be applied to future formulations. We recommend that repeat food effect studies should be approached on a case-by-case basis taking into account the totality of the evidence including the use of PBPK modeling.

2022-12-01·Journal of Pharmaceutical Sciences

Elucidating a Potential Mechanism of Permeability Enhancer Sodium N-[8-(2-hydroxybenzoyl) amino] Caprylate in Rats: Evidence of Lymphatic Absorption of Cyanocobalamin using the Mesenteric Lymph Duct Cannulated Rat

Article

作者: Wu, Ricky ; Liu, Jia ; Nagapudi, Karthik ; Durk, Matthew R ; Chiang, Po-Chang ; Dolton, Michael ; Plise, Emile ; Liu, Liling ; Chen, Jacob

Oral administration is the most popular and convenient route for drug delivery, yet the success of oral drug delivery is dependent on the ADME properties of the drug. Among those ADME properties, permeability is considered one of the key attributes for successful oral drug absorption. Hence, the utilization of permeability enhancers to improve drug oral absorption is an important area of research in drug delivery. A multitude of data suggests that sodium N-[8-(2-hydroxybenzoyl) amino] caprylate (SNAC) is an effective permeability enhancer. Despite its success, the mechanism of how SNAC works to enhance the oral absorption of compounds is poorly understood. To better understand how SNAC worked, we investigated the hypothesis of SNAC promotes lymphatic absorption of target compounds. In this study, cyanocobalamin was used as the model compound and mesenteric lymph duct cannulated rats were used to investigate its absorption with or without SNAC. The present study demonstrated that SNAC enhanced the lymphatic absorption of cyanocobalamin when the two were co-dosed in rats. Furthermore, levels of SNAC in lymph fluid and the systemic circulation were higher when co-dosed with cyanocobalamin.

2022-08-01·JAMA Neurology

A Randomized Clinical Trial

Article

作者: Ward, Michael ; Nair, Anil ; Shah, Raj ; Sanabria Bohorquez, Sandra ; Ratajczak, Marcin ; Cassetta, Emanuele ; Tartaglia, Maria Carmela ; Dubois, Bruno ; Omidvar, Omid ; Goodman, Ira ; Edwards, Keith ; Russell, David ; Zielinski, Tomasz ; Ilkowski, Jan ; Zboch, Marzena ; Östlund, Henrik ; Levey, Allan ; Pasquier, Florence ; MacSweeney, Josephine Emer ; Dobryniewski, Jacek ; Schaerf, Frederick ; Hart, David ; Belliard, Serge ; Viñuela Fernandez, Félix ; O'Brien, Terence ; Baquero Toledo, Miquel ; Blendstrup, Mira ; Pierce, Aimee ; Rosenbloom, Michael ; Farnbach, Peter ; Porsteinsson, Anton ; Weisman, David ; Black, Sandra ; Alexandersen, Peter ; Turner, Raymond ; Sajjadi, Seyed Ahmad ; Cohen, Sharon ; Brody, Mark ; Watson, David ; Justesen, Annette ; Prins, Niels ; Czarnecki, Maciej ; Teng, Edmond ; Smith, William ; Stein, Lee ; Ala, Thomas ; Bruno, Giuseppe ; Salloway, Stephen ; von Arnim, Christine ; Bond, Wendy ; Kyndt, Chris ; Peters, Oliver ; Abizanda Soler, Pedro ; Anthony, Pierre ; Geldmacher, David ; Sanchez Del Valle Diaz, Raquel ; Sood, Ajay ; Kucharski, Robert ; Sha, Sharon ; Justiz, William ; Klodowska, Gabriela ; Nielsen, Soren ; Agronin, Marc ; Del Olmo Rodriguez, Antonio ; Sikkes, Sietske A. M. ; Krupinski, Jerzy ; Blanc, Frédéric ; Stoukides, John ; McElveen, William Alvin ; Oskooilar, Nader ; Nair, Malini ; Ceccaldi, Mathieu ; Polivka, Dörte ; Dolton, Michael ; Agüera Morales, Eduardo ; Losk, Scott ; Murphy, Cynthia ; Vandenberghe, Rik ; Yassi, Nawaf ; Dautzenberg, Paul ; Ramakrishnan, Vidya ; Linazasoro Cristobal, Gurutz ; De Lena, Carlo ; Frank, Andrew ; López Arrieta, Jesús ; Boada Rovira, Mercè ; Marshall, Gad ; Grimmer, Timo ; Nisker, William ; Honig, Lawrence ; Krygowska-Wajs, Anna ; Vanhee, Frederik ; Kottke-Arbeiter, Monika Elisabeth ; Riverol Fernandez, Mario ; Rutgers, Sterre ; Bergeron, Richard ; Mummery, Catherine ; Blesa González, Rafael ; Fuji, Reina N. ; Lieten, Siddhartha ; Forchetti, Concetta ; Areovimata, Anna ; Schwartz, Raymond ; Manser, Paul T. ; Toth, Bali ; Mickielewicz, Anatol ; Sharma, Sanjiv ; Laske, Christoph ; Pickthorn, Karen ; Logroscino, Giancarlo ; Maldonado-Robles, Orlando ; Wildsmith, Kristin R. ; Bobbala, Ashwini ; Brunstein, Flavia ; Goldstein, Mark ; Mollion, Hélène ; Thein, Stephen ; Kerchner, Geoffrey A. ; Jonsson, Michael ; Centonze, Diego ; Krolak-Salmon, Pierre ; McAllister, Peter ; Martinez, Walter

ImportanceNeurofibrillary tangles composed of aggregated tau protein are one of the neuropathological hallmarks of Alzheimer disease (AD) and correlate with clinical disease severity. Monoclonal antibodies targeting tau may have the potential to ameliorate AD progression by slowing or stopping the spread and/or accumulation of pathological tau.ObjectiveTo evaluate the safety and efficacy of the monoclonal anti-tau antibody semorinemab in prodromal to mild AD.Design, Setting, and ParticipantsThis phase 2 randomized, double-blind, placebo-controlled, parallel-group clinical trial was conducted between October 18, 2017, and July 16, 2020, at 97 sites in North America, Europe, and Australia. Individuals aged 50 to 80 years (inclusive) with prodromal to mild AD, Mini-Mental State Examination scores between 20 and 30 (inclusive), and confirmed β-amyloid pathology (by positron emission tomography or cerebrospinal fluid) were included.InterventionsDuring the 73-week blinded study period, participants received intravenous infusions of placebo or semorinemab (1500 mg, 4500 mg, or 8100 mg) every 2 weeks for the first 3 infusions and every 4 weeks thereafter.Main Outcomes and MeasuresThe primary outcomes were change from baseline on the Clinical Dementia Rating-Sum of Boxes score from baseline to week 73 and assessments of the safety and tolerability for semorinemab compared with placebo.ResultsIn the modified intent-to-treat cohort (n = 422; mean [SD] age, 69.6 [7.0] years; 235 women [55.7%]), similar increases were seen on the Clinical Dementia Rating-Sum of Boxes score in the placebo (n = 126; Δ = 2.19 [95% CI, 1.74-2.63]) and semorinemab (1500 mg: n = 86; Δ = 2.36 [95% CI, 1.83-2.89]; 4500 mg: n = 126; Δ = 2.36 [95% CI, 1.92-2.79]; 8100 mg: n = 84; Δ = 2.41 [95% CI, 1.88-2.94]) arms. In the safety-evaluable cohort (n = 441), similar proportions of participants experienced adverse events in the placebo (130 [93.1%]) and semorinemab (1500 mg: 89 [88.8%]; 4500 mg: 132 [94.7%]; 8100 mg: 90 [92.2%]) arms.Conclusions and RelevanceIn participants with prodromal to mild AD in this randomized clinical trial, semorinemab did not slow clinical AD progression compared with placebo throughout the 73-week study period but did demonstrate an acceptable and well-tolerated safety profile. Additional studies of anti-tau antibodies may be needed to determine the clinical utility of this therapeutic approach.Trial RegistrationClinicalTrials.gov Identifier: NCT03289143.

项与 Roche Products Pty Ltd. 相关的新闻（医药）

2024-02-19

·Business Wire

The Pharmaceutical Industry in South Africa 2023 - Profiles of 120+ Companies Including Aspen Pharmacare, Adcock Ingram, Bayer, GlaxoSmithKline, Pfizer, Clicks, Dis-Chem & Nativa - ResearchAndMarkets.com

DUBLIN--( BUSINESS WIRE )--The "Pharmaceutical Industry in South Africa 2023" report has been added to ResearchAndMarkets.com's offering. More than 80% of South African pharmaceutical manufacturing and distribution revenue is from the private sector. State purchases of pharmaceuticals are declining, and manufacturers' margins are under pressure due to low regulated price increases for scheduled pharmaceuticals in a high inflation environment. In the retail sector Clicks and Dis-Chem have wholesale volume advantages and an ever-increasing footprint. Consumer spending patterns have forced consolidation in the retail sector, the growth of private label sales, growth in convenience formats, and diversification into new services and products. There has been a flurry of investments in localising vaccine raw material and finished dose manufacturing, although the sustainability of these initiatives is far from secure. Key Opportunities Cannabis cultivation, processing and medical product manufacturing Rapid growth in generic sales making medicine more affordable Strong R&D and advanced manufacturing capabilities may attract investment Challenges Growing concentration of wholesale and retail pharmacy supply. Low regulated medicine price increases in the context of high international inflation. Poor economic growth constraining consumer spending on healthcare. Reduced government budgets for medicines restricting local opportunities in the face of cheaper international competition. South Africa's dependence on imported active ingredients. Sustaining local vaccine manufacturing in the face of declining demand. Trends A shift from reactive medicine to preventative healthcare resulting in demand for immunity-building vitamins, tonics, minerals and supplements. Focus on research and development, particularly drugs and therapies targeting COVID-19, HIV/Aids, TB, malaria, cancer, and chronic diseases. Growing pressure on pharmaceutical companies to improve access to healthcare by making medicines more affordable. Increased focus on localisation, including local sourcing of inputs and the development of local manufacturing capacity. Recovery of demand as elective surgery and procedures and illnesses such as flu return to pre-pandemic patterns. Small community pharmacies are finding it difficult to compete with large retail businesses. Outlook The pharmaceutical industry is well developed and supported by strong R&D and advanced manufacturing capabilities, including biotechnology manufacturing facilities. The Department of Health's affordable medicines programme has been instrumental in lowering scheduled pharmaceutical prices, particularly in the public sector. Investments in vaccine manufacture have begun to address South Africa's exposure to vulnerabilities and dependence on active pharmaceutical ingredient and vaccine imports. These investments have strengthened South Africa's position as the hub for sub-Saharan African pharmaceutical research, development, and supply. However, vaccine demand has dropped and doses are being donated to African countries. Margin pressure is expected to grow as the economy remains poor and restraints on consumer spending intensify. The implementation of the National Health Insurance is likely to put further pressure on manufacturers and wholesalers to reduce medicine prices. Report Coverage This report on the pharmaceutical industry in South Africa provides comprehensive information on the manufacturing, wholesale and retail subsectors, price regulation, medical cannabis, market shares, notable multinational and local players and corporate actions. There are profiles of 128 companies including local dominant players Aspen Pharmacare and Adcock Ingram, multinationals such as Bayer, GlaxoSmithKline and Pfizer and retailers Clicks and Dis-Chem and other players such as Nativa. COMPANY PROFILES Abbott Laboratories South Africa (Pty) Ltd Acino Healthcare Group (Pty) Ltd Adcock Ingram Holdings Ltd African Medicines (Pty) Ltd Afrigen Biologics (Pty) Ltd Afriplex (Pty) Ltd AIM Africa Alpha Pharm (Pty) Ltd Amka Products (Pty) Ltd Amway South Africa (Pty) Ltd Arrie Nel Pharmacy Group (Pty) Ltd Ascendis Health Ltd Aspen Pharmacare Holdings Ltd Astellas Pharma (Pty) Ltd AstraZeneca Pharmaceuticals (Pty) Ltd Aurobindo Pharma (Pty) Ltd Austell Pharmaceuticals (Pty) Ltd B Braun Medical (Pty) Ltd Barrs Pharmaceuticals Industries (Pty) Ltd Baxter Healthcare South Africa (Pty) Ltd Bayer (Pty) Ltd Becton Dickinson (Pty) Ltd Bio Earth Manufacturing (Pty) Ltd Biologicals and Vaccines Institute of Southern Africa (Pty) Ltd (The) Bitek Industries (Pty) Ltd California Pharmaceuticals (Pty) Ltd Caprichem (Pty) Ltd Chemical Convertors (Pty) Ltd Chemtron Holdings (Pty) Ltd Cilo Cybin Pharmaceutical (Pty) Ltd Cipla Medpro South Africa (Pty) Ltd Columbia Pharmaceuticals (Pty) Ltd CoMED Health (Pty) Ltd Deon Schoeman CC Dis-Chem Pharmacies Ltd Dr Reddy's Laboratories (Pty) Ltd DSV Solutions (Pty) Ltd Dynachem (Pty) Ltd Ecolab (Pty) Ltd Eli Lilly (S A) (Pty) Ltd Evohealth (Pty) Ltd Felbridge (Pty) Ltd Ferring (Pty) Ltd Forever Living Products South Africa (Pty) Ltd Fresenius Kabi Manufacturing SA (Pty) Ltd Fresenius Kabi South Africa (Pty) Ltd G M Pharmaceuticals (Pty) Ltd GlaxoSmithKline South Africa (Pty) Ltd Glenmark Pharmaceuticals South Africa (Pty) Ltd Goodleaf Company (Pty) Ltd (The) Gulf Drug Company (Pty) Ltd H H Durrheim (Pty) Ltd Herba Zone (Pty) Ltd Herbalife International South Africa Ltd Hersol Manufacturing Laboratories (Pty) Ltd Hymed (Pty) Ltd IMBC Investment (Pty) Ltd iMvula Healthcare Logistics (Pty) Ltd Infection Protection Products (Pty) Ltd Ingelheim Pharmaceuticals (Pty) Ltd Iszipharm Pharmaceutical Distributors (Pty) Ltd Joe Soap CC Johnson and Johnson (Pty) Ltd Kellogg Company of South Africa (Pty) Ltd Kevali Chemical Group (Pty) Ltd Lakato (Pty) Ltd Leaf Botanicals (Pty) Ltd MedCan (Pty) Ltd Medichem (Pty) Ltd Mega Magic CC Merck (Pty) Ltd MSD (Pty) Ltd National Bioproducts Institute NPC Nativa (Pty) Ltd NeoLife International (Pty) Ltd Nestle (South Africa) (Pty) Ltd Netcare Pharmacies (Pty) Ltd Netcare Pharmacies 2 (Pty) Ltd New Clicks South Africa (Pty) Ltd Nkunzi Pharmaceuticals (Pty) Ltd Novartis South Africa (Pty) Ltd Omnia Holdings Ltd Organon South Africa (Pty) Ltd P and G South African Trading (Pty) Ltd Parceval (Pty) Ltd Pfizer Laboratories (Pty) Ltd Pharma Dynamics (Pty) Ltd Pharmaceutical Enterprises (Pty) Ltd Pharmacy Direct (Pty) Ltd Pharmacyweb Holdings (Pty) Ltd PharmaForce (Pty) Ltd Pharmed Pharmaceuticals (Pty) Ltd Pick n Pay Stores Ltd Platchem (Pty) Ltd Prime Cleaning Suppliers (Pty) Ltd Ranbaxy (S A) (Pty) Ltd Ranbaxy Pharmaceuticals (Pty) Ltd Reckitt Benckiser Pharmaceuticals (Pty) Ltd Releaf Pharmaceuticals (Pty) Ltd Richbay Chemicals (Pty) Ltd Roche Products (Pty) Ltd S A F I C (Pty) Ltd S A Natural Products (Pty) Ltd S Buys (Pty) Ltd Safarmex (Pty) Ltd Safety Chemicals (Pty) Ltd Sandoz South Africa (Pty) Ltd Sanofi Industries South Africa (Pty) Ltd Sanofi-Aventis South Africa (Pty) Ltd Shoprite Holdings Ltd Solgar South Africa (Pty) Ltd Sonke Pharmaceuticals (Pty) Ltd South African Nuclear Energy Corporation SOC Ltd (The) SPAR Group Ltd (The) Specialised Maintenance Products (Pty) Ltd Specpharm Holdings (Pty) Ltd Spectank (Pty) Ltd Tevo (Pty) Ltd Tiger Brands Ltd Topmed Health Care Distributors (Pty) Ltd Touchless Germ Control Western Cape CC Transpharm (Pty) Ltd Unilever South Africa (Pty) Ltd Viatris South Africa (Pty) Ltd Vital Health Foods (Pty) Ltd Waco Africa (Pty) Ltd Wellness Warehouse (Pty) Ltd Woolworths Holdings Ltd For more information about this report visit https://www.researchandmarkets.com/r/chrnzo About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

疫苗

2024-02-12

·PRNewswire

South Africa Pharmaceutical Industry Report - Shift from Reactive Medicine to Preventative Healthcare Resulting in Demand for Immunity-building Vitamins, Tonics, Minerals and Supplements

DUBLIN, Feb. 12, 2024 /PRNewswire/ -- The "Pharmaceutical Industry in South Africa 2023" report has been added to ResearchAndMarkets.com's offering. More than 80% of South African pharmaceutical manufacturing and distribution revenue is from the private sector. State purchases of pharmaceuticals are declining, and manufacturers' margins are under pressure due to low regulated price increases for scheduled pharmaceuticals in a high inflation environment. In the retail sector Clicks and Dis-Chem have wholesale volume advantages and an ever-increasing footprint. Consumer spending patterns have forced consolidation in the retail sector, the growth of private label sales, growth in convenience formats, and diversification into new services and products. There has been a flurry of investments in localising vaccine raw material and finished dose manufacturing, although the sustainability of these initiatives is far from secure. Key Opportunities Cannabis cultivation, processing and medical product manufacturing Rapid growth in generic sales making medicine more affordable Strong R&D and advanced manufacturing capabilities may attract investment Challenges Growing concentration of wholesale and retail pharmacy supply. Low regulated medicine price increases in the context of high international inflation. Poor economic growth constraining consumer spending on healthcare. Reduced government budgets for medicines restricting local opportunities in the face of cheaper international competition. South Africa's dependence on imported active ingredients. Sustaining local vaccine manufacturing in the face of declining demand. Trends A shift from reactive medicine to preventative healthcare resulting in demand for immunity-building vitamins, tonics, minerals and supplements. Focus on research and development, particularly drugs and therapies targeting COVID-19, HIV/Aids, TB, malaria, cancer, and chronic diseases. Growing pressure on pharmaceutical companies to improve access to healthcare by making medicines more affordable. Increased focus on localisation, including local sourcing of inputs and the development of local manufacturing capacity. Recovery of demand as elective surgery and procedures and illnesses such as flu return to pre-pandemic patterns. Small community pharmacies are finding it difficult to compete with large retail businesses. Outlook The pharmaceutical industry is well developed and supported by strong R&D and advanced manufacturing capabilities, including biotechnology manufacturing facilities. The Department of Health's affordable medicines programme has been instrumental in lowering scheduled pharmaceutical prices, particularly in the public sector. Investments in vaccine manufacture have begun to address South Africa's exposure to vulnerabilities and dependence on active pharmaceutical ingredient and vaccine imports. These investments have strengthened South Africa's position as the hub for sub-Saharan African pharmaceutical research, development, and supply. However, vaccine demand has dropped and doses are being donated to African countries. Margin pressure is expected to grow as the economy remains poor and restraints on consumer spending intensify. The implementation of the National Health Insurance is likely to put further pressure on manufacturers and wholesalers to reduce medicine prices. Report Coverage This report on the pharmaceutical industry in South Africa provides comprehensive information on the manufacturing, wholesale and retail subsectors, price regulation, medical cannabis, market shares, notable multinational and local players and corporate actions. There are profiles of 128 companies including local dominant players Aspen Pharmacare and Adcock Ingram, multinationals such as Bayer, GlaxoSmithKline and Pfizer and retailers Clicks and Dis-Chem and other players such as Nativa. COMPANY PROFILES Abbott Laboratories South Africa (Pty) Ltd Acino Healthcare Group (Pty) Ltd Adcock Ingram Holdings Ltd African Medicines (Pty) Ltd Afrigen Biologics (Pty) Ltd Afriplex (Pty) Ltd AIM Africa Alpha Pharm (Pty) Ltd Amka Products (Pty) Ltd Amway South Africa (Pty) Ltd Arrie Nel Pharmacy Group (Pty) Ltd Ascendis Health Ltd Aspen Pharmacare Holdings Ltd Astellas Pharma (Pty) Ltd AstraZeneca Pharmaceuticals (Pty) Ltd Aurobindo Pharma (Pty) Ltd Austell Pharmaceuticals (Pty) Ltd B Braun Medical (Pty) Ltd Barrs Pharmaceuticals Industries (Pty) Ltd Baxter Healthcare South Africa (Pty) Ltd Bayer (Pty) Ltd Becton Dickinson (Pty) Ltd Bio Earth Manufacturing (Pty) Ltd Biologicals and Vaccines Institute of Southern Africa (Pty) Ltd (The) Bitek Industries (Pty) Ltd California Pharmaceuticals (Pty) Ltd Caprichem (Pty) Ltd Chemical Convertors (Pty) Ltd Chemtron Holdings (Pty) Ltd Cilo Cybin Pharmaceutical (Pty) Ltd Cipla Medpro South Africa (Pty) Ltd Columbia Pharmaceuticals (Pty) Ltd CoMED Health (Pty) Ltd Deon Schoeman CC Dis-Chem Pharmacies Ltd Dr Reddy's Laboratories (Pty) Ltd DSV Solutions (Pty) Ltd Dynachem (Pty) Ltd Ecolab (Pty) Ltd Eli Lilly (S A) (Pty) Ltd Evohealth (Pty) Ltd Felbridge (Pty) Ltd Ferring (Pty) Ltd Forever Living Products South Africa (Pty) Ltd Fresenius Kabi Manufacturing SA (Pty) Ltd Fresenius Kabi South Africa (Pty) Ltd G M Pharmaceuticals (Pty) Ltd GlaxoSmithKline South Africa (Pty) Ltd Glenmark Pharmaceuticals South Africa (Pty) Ltd Goodleaf Company (Pty) Ltd (The) Gulf Drug Company (Pty) Ltd H H Durrheim (Pty) Ltd Herba Zone (Pty) Ltd Herbalife International South Africa Ltd Hersol Manufacturing Laboratories (Pty) Ltd Hymed (Pty) Ltd IMBC Investment (Pty) Ltd iMvula Healthcare Logistics (Pty) Ltd Infection Protection Products (Pty) Ltd Ingelheim Pharmaceuticals (Pty) Ltd Iszipharm Pharmaceutical Distributors (Pty) Ltd Joe Soap CC Johnson and Johnson (Pty) Ltd Kellogg Company of South Africa (Pty) Ltd Kevali Chemical Group (Pty) Ltd Lakato (Pty) Ltd Leaf Botanicals (Pty) Ltd MedCan (Pty) Ltd Medichem (Pty) Ltd Mega Magic CC Merck (Pty) Ltd MSD (Pty) Ltd National Bioproducts Institute NPC Nativa (Pty) Ltd NeoLife International (Pty) Ltd Nestle (South Africa) (Pty) Ltd Netcare Pharmacies (Pty) Ltd Netcare Pharmacies 2 (Pty) Ltd New Clicks South Africa (Pty) Ltd Nkunzi Pharmaceuticals (Pty) Ltd Novartis South Africa (Pty) Ltd Omnia Holdings Ltd Organon South Africa (Pty) Ltd P and G South African Trading (Pty) Ltd Parceval (Pty) Ltd Pfizer Laboratories (Pty) Ltd Pharma Dynamics (Pty) Ltd Pharmaceutical Enterprises (Pty) Ltd Pharmacy Direct (Pty) Ltd Pharmacyweb Holdings (Pty) Ltd PharmaForce (Pty) Ltd Pharmed Pharmaceuticals (Pty) Ltd Pick n Pay Stores Ltd Platchem (Pty) Ltd Prime Cleaning Suppliers (Pty) Ltd Ranbaxy (S A) (Pty) Ltd Ranbaxy Pharmaceuticals (Pty) Ltd Reckitt Benckiser Pharmaceuticals (Pty) Ltd Releaf Pharmaceuticals (Pty) Ltd Richbay Chemicals (Pty) Ltd Roche Products (Pty) Ltd S A F I C (Pty) Ltd S A Natural Products (Pty) Ltd S Buys (Pty) Ltd Safarmex (Pty) Ltd Safety Chemicals (Pty) Ltd Sandoz South Africa (Pty) Ltd Sanofi Industries South Africa (Pty) Ltd Sanofi-Aventis South Africa (Pty) Ltd Shoprite Holdings Ltd Solgar South Africa (Pty) Ltd Sonke Pharmaceuticals (Pty) Ltd South African Nuclear Energy Corporation SOC Ltd (The) SPAR Group Ltd (The) Specialised Maintenance Products (Pty) Ltd Specpharm Holdings (Pty) Ltd Spectank (Pty) Ltd Tevo (Pty) Ltd Tiger Brands Ltd Topmed Health Care Distributors (Pty) Ltd Touchless Germ Control Western Cape CC Transpharm (Pty) Ltd Unilever South Africa (Pty) Ltd Viatris South Africa (Pty) Ltd Vital Health Foods (Pty) Ltd Waco Africa (Pty) Ltd Wellness Warehouse (Pty) Ltd Woolworths Holdings Ltd For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

疫苗

2024-01-02

·Business Wire

South Africa Medical and Surgical Equipment Supply and Manufacturing Industry Report 2023 Featuring Medtronic, Johnson & Johnson, Siemens, Southern Medical, CapeRay and Ascendis - ResearchAndMarkets.com

DUBLIN--( BUSINESS WIRE )--The "The Supply and Manufacture of Medical and Surgical Equipment Industry in South Africa 2023" report has been added to ResearchAndMarkets.com's offering. This report on the manufacture and supply of medical and surgical equipment and orthopaedic appliances in South Africa includes information on the state of the sector, the main devices used and imported, utilisation of healthcare services using medical technology, licences, notable players and technology and innovation. South Africa's medical devices industry consists of mostly small to medium enterprises and larger multinational companies with local subsidiaries or partners. The latter dominate the industry as imports account for as much as 90% of the market. Disposable devices make up the largest share followed by diagnostic imaging. The public sector accounts for almost half of healthcare expenditure but serves most of the population, and the private sector is better resourced with medical devices. There are profiles of 65 companies including international companies present in South Africa such as Medtronic, Johnson & Johnson Medical, Siemens, notable pharmaceutical wholesalers and retailers, and other notable players such Southern Medical, CapeRay and Ascendis. Demand The need for medical devices is underpinned by the prevalence of communicable and non-communicable diseases and trauma, as well as an ageing population. These factors have not necessarily led to higher demand due to low economic growth resulting in a real decline in health budgets and high levels of unemployment leading to stagnant medical scheme membership and/or switching to cheaper plans. Of the public funding available, considerable amounts have been lost through corruption. Private medical insurance is largely unaffordable, increasing price sensitivity for devices. Key Trends Local suppliers compete with entrenched global companies. Various initiatives have been launched to improve collaboration and competition including the Medical Device and Diagnostic Innovation Cluster. Medical telematic technology is being used to provide services to manage patients from home. There is a move towards cheaper medical aid packages due to affordability issues. Key Topics Covered: 1. INTRODUCTION 2. DESCRIPTION OF THE INDUSTRY 2.1. Industry Value Chain 2.2. Geographic Position 2.3. Size of the Industry 3. LOCAL 3.1. State of the Industry 3.2. Key Trends 3.3. Key Issues 3.4. Notable Players 3.5. Trade 3.6. Corporate Actions 3.7. Regulations 3.8. Enterprise Development and Social Development 4. AFRICA 5. INTERNATIONAL 6. INFLUENCING FACTORS 6.1. Unforeseen Events 6.2. Economic Environment 6.3. Labour 6.4. Environmental Issues 6.5. Technology, R&D, Innovation 6.6. Government Support 6.7. Input Costs 7. COMPETITIVE ENVIRONMENT 7.1. Competition 7.2. Ownership Structure of the Industry 7.3. Barriers to Entry 8. SWOT ANALYSIS 9. OUTLOOK 10. INDUSTRY ASSOCIATIONS 11. REFERENCES 11.1. Publications 11.2. Websites APPENDICES Appendix 1 - Summary of Notable Players COMPANY PROFILES A P S Terapie Suid-Afrika CC Acino Healthcare Group (Pty) Ltd Ascendis Health Ltd B Braun Medical (Pty) Ltd Baxter Healthcare South Africa (Pty) Ltd Becton Dickinson (Pty) Ltd Brittan Healthcare (Pty) Ltd BSN Medical (Pty) Ltd CapeRay Medical (Pty) Ltd Capricorn Biomedical (Pty) Ltd CE Mobility Wheelchairs (Pty) Ltd Cerdak (Pty) Ltd Champion Health Care (Pty) Ltd Consulens Medical Healthcare Solutions (Pty) Ltd Demant South Africa (Pty) Ltd Dis-Chem Pharmacies Ltd Drager South Africa (Pty) Ltd Electro Spyres Medical (Pty) Ltd Elite Surgical Supplies (Pty) Ltd Evergreen Latex CC Fluoro Vizion (Pty) Ltd Fortis X (Pty) Ltd Fresenius Kabi Manufacturing SA (Pty) Ltd Fresenius Kabi South Africa (Pty) Ltd Fresenius Medical Care South Africa (Pty) Ltd G and S Medical Supplies CC Gabler Medical (Pty) Ltd GE Healthcare (Pty) Ltd Grobir Medical Suppliers (Pty) Ltd Hutz Hospi Tec (Pty) Ltd IDT Diagnostics CC iMvula Healthcare Logistics (Pty) Ltd Johnson and Johnson Medical (Pty) Ltd Lodox Systems (Pty) Ltd M and L Medical Suppliers CC Medi-Safe Surgicals (Pty) Ltd Medical Diagnostech (Pty) Ltd Medical Innovations (Pty) Ltd Medinox (Pty) Ltd Medtronic (Africa) (Pty) Ltd Megrotex (Pty) Ltd Minoan Medical (Pty) Ltd MouldProd Exhibitions Ltd Multisurge (Pty) Ltd New Clicks South Africa (Pty) Ltd Ntshatsheli Trading (Pty) Ltd Orthopaedic Suppliers CC Philips South Africa Commercial (Pty) Ltd Radical Mobility (Pty) Ltd Roche Diabetes Care South Africa (Pty) Ltd Roche Products (Pty) Ltd S A Biomedical (Pty) Ltd SafMed (Pty) Ltd Shonaquip (Pty) Ltd Siemens (Pty) Ltd Sinapi Biomedical (Pty) Ltd Southern Implants (Pty) Ltd Southern Medical (Pty) Ltd SSEM Mthembu Medical (Pty) Ltd Stryker South Africa (Pty) Ltd Teleflex Medical (Pty) Ltd Ti-TaMED (Pty) Ltd Vertice Healthcare (Pty) Ltd VoiceAmp (Pty) Ltd Welch Allyn South Africa (Pty) Ltd Companies Mentioned A P S Terapie Suid-Afrika CC Acino Healthcare Group (Pty) Ltd Ascendis Health Australia Pty Ltd Ascendis Health Europe Holdings Sarl Ascendis Health Ltd B Braun Medical (Pty) Ltd Baxter Healthcare South Africa (Pty) Ltd Becton Dickinson (Pty) Ltd Brittan Healthcare (Pty) Ltd BSN Medical (Pty) Ltd CapeRay Medical (Pty) Ltd Capricorn Biomedical (Pty) Ltd Cardio Tech (Pty) Ltd CE Mobility Wheelchairs (Pty) Ltd Cerdak (Pty) Ltd Champion Health Care (Pty) Ltd Consulens Medical Healthcare Solutions (Pty) Ltd Demant South Africa (Pty) Ltd Dis-Chem Airport Junction (Pty) Ltd Dis-Chem Gallo Shopping Centre Francistown (Pty) Ltd Dis-Chem Pharmacies Ltd Dis-Chem The Fields (Pty) Ltd Dis-Chem Walvis Bay (Pty) Ltd Dis-Chem Wernhill (Pty) Ltd Dis-Chem Westville Junction Pharmacy (Pty) Ltd Drager South Africa (Pty) Ltd Electro Spyres Medical (Pty) Ltd Elite Surgical Supplies (Pty) Ltd Evergreen Latex CC Fluoro Vizion (Pty) Ltd Fortis X (Pty) Ltd Fresenius Kabi Manufacturing SA (Pty) Ltd Fresenius Kabi South Africa (Pty) Ltd Fresenius Medical Care South Africa (Pty) Ltd G and S Medical Supplies CC Gabler Medical (Pty) Ltd GE Healthcare (Pty) Ltd Grobir Medical Suppliers (Pty) Ltd Hutz Hospi Tec (Pty) Ltd IDT Diagnostics CC iMvula Healthcare Logistics (Pty) Ltd Interv Med (Pty) Ltd Johnson and Johnson Medical (Pty) Ltd Lodox Systems (Pty) Ltd M and L Medical Suppliers CC Medi-Safe Surgicals (Pty) Ltd Medical Diagnostech (Pty) Ltd Medical Innovations (Pty) Ltd Medical Medtronic Nigeria Ltd Medinox (Pty) Ltd Medtronic (Africa) (Pty) Ltd Megrotex (Pty) Ltd Minoan Medical (Pty) Ltd MouldProd Exhibitions Ltd Multisurge (Pty) Ltd New Clicks South Africa (Pty) Ltd Ntshatsheli Trading (Pty) Ltd Orthopaedic Suppliers CC Philips South Africa Commercial (Pty) Ltd Radical Mobility (Pty) Ltd Respiratory Care Africa (Botswana) (Pty) Ltd Roche Diabetes Care South Africa (Pty) Ltd Roche Products (Pty) Ltd S A Biomedical (Pty) Ltd SafMed (Pty) Ltd Shonaquip (Pty) Ltd Siemens (Pty) Ltd Sinapi Biomedical (Pty) Ltd Southern Implants (Pty) Ltd Southern Medical (Pty) Ltd SSEM Mthembu Medical (Pty) Ltd Stryker South Africa (Pty) Ltd Taurus Chemicals Namibia (Pty) Ltd Teleflex Medical (Pty) Ltd Ti-TaMED (Pty) Ltd Tony Ferguson Weightloss SA (Pty) Ltd Vertice Healthcare (Pty) Ltd VoiceAmp (Pty) Ltd Welch Allyn South Africa (Pty) Ltd For more information about this report visit https://www.researchandmarkets.com/r/flhthj About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

100 项与 Roche Products Pty Ltd. 相关的药物交易

登录后查看更多信息

100 项与 Roche Products Pty Ltd. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2024年11月05日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

批准上市

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

恩美曲妥珠单抗 ( HER2 x Tubulin )	HER2阳性乳腺癌更多	批准上市
法瑞西单抗 ( Ang2 x VEGF-A )	湿性年龄相关性黄斑变性更多	批准上市
卡西瑞单抗/伊德单抗 ( SARS-CoV-2 S protein )	新型冠状病毒感染更多	批准上市
普拉替尼 ( RET )	RET融合阳性甲状腺癌更多	批准上市
异维A酸 ( RARs )	囊性痤疮更多	批准上市